Moso Michael A, Sasadeusz Joe, Morrissey Catherine O, Bond Katherine, Guy Stephen, Slavin Monica A, Dendle Claire
Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Intern Med J. 2023 Apr;53(4):619-624. doi: 10.1111/imj.16064. Epub 2023 Apr 3.
Coronavirus disease 2019 (COVID-19) in immunocompromised patients can lead to severe and prolonged illness. Data are limited with regard to management of COVID-19 in this setting, particularly in persistent or recrudescent infection. The authors conducted an online survey among infectious diseases doctors to determine current approaches to treatment across Australasia. There was marked variability in responses relating to the diagnostic modalities and use of antiviral agents in patients with immunocompromise, highlighting the need for high-quality studies to guide treatment decisions in this group.
2019冠状病毒病（COVID-19）在免疫功能低下患者中可导致严重且病程迁延的疾病。关于在这种情况下COVID-19的管理，尤其是持续性或复发性感染的管理，数据有限。作者对传染病医生进行了一项在线调查，以确定澳大利亚和新西兰当前的治疗方法。在免疫功能低下患者的诊断方式和抗病毒药物使用方面，回答存在显著差异，这突出表明需要高质量研究来指导该群体的治疗决策。
